Riluzole, a glutamate modulator is approved for amyotrophic lateral sclerosis (ALS).[40, 41] Our previous study showed that the disrupted synapse formation and function in WFS1‐deficient human cerebral organoids could be efficiently reversed with riluzole treatment.[26] To verify the impact of riluzole on apoptosis in the cerebral organoids induced by WFS1 deficiency, human cerebral organoids were treated with 5 × 10−6m riluzole for 5 d. This evidence concerns the gene WFS1 and amyotrophic lateral sclerosis.